To be or not to be a case of heparin resistance

To be or not to be a case of heparin resistance

Heparin resistance can be defined as high doses of unfractionated heparin (UFH), greater than 35,000 IU/day, required to raise the activated partial thromboplastin time (aPTT) and activated coagulation time (ACT) to within therapeutically desired ranges or the impossibility of doing so. The most com...

Full description

Bibliographic Details
Main Authors:	Jibran Durrani, Faizan Malik, Naveed Ali, Syed Imran Mustafa Jafri
Format:	Article
Language:	English
Published:	Greater Baltimore Medical Center 2018-05-01
Series:	Journal of Community Hospital Internal Medicine Perspectives
Subjects:	Activated partial thromboplastin time (aPTT) anti-thrombin III (ATIII) activated coagulation time (ACT) unfractionated heparin(UFH) low molecular weight heparin(LMWH) anti-factor 10a (AF 10a) pulmonary embolism (PE) disseminated intravascular coagulation (DIC)
Online Access:	http://dx.doi.org/10.1080/20009666.2018.1466599

Similar Items

Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement
by: Benjamin Lardinois, et al.
Published: (2022-02-01)

Heparins: A Shift of Paradigm
by: H. Coenraad Hemker, et al.
Published: (2019-11-01)

The use of activated partial thromboplastin time versus antifactor Xa assay in monitoring continuous unfractionated heparin infusion therapy in obstetric intensive care unit
by: Hany V. Zaki, et al.
Published: (2019-02-01)

Inactivation of Heparin by Cationically Modified Chitosan
by: Barbara Lorkowska-Zawicka, et al.
Published: (2014-06-01)

LMWHs have additional advantage over unfractionated heparin: no volume load
by: GP Koracevic
Published: (2009-10-01)

Comparison of aPTT and CT Parameter of the ROTEM Test to Monitor Heparin Anti-Coagulation Effect in ICU Patients: an Observational Study
by: Atabak Najafi, et al.
Published: (2015-10-01)

Is It Rational to Study Coagulations Test Routinely before Operations and Invasive Procedure: Single Center Retrospective Study
by: Fergün Yılmaz, et al.
Published: (2019-07-01)

Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!
by: Rita Carlotta Santoro, et al.
Published: (2023-06-01)

Effects of thrombomodulin alfa on hemostatic parameters in disseminated intravascular coagulation: Post hoc analysis of a phase 3 randomized controlled trial
by: Takashi Ito, et al.
Published: (2020-10-01)

Laboratory Assessment of Unfractionated Heparin (UFH) with Activated Clotting Time (ACT) and Anti-Xa Activity during Peripheral Arterial Angiographic Procedure
by: Tuukka Helin, et al.
Published: (2023-04-01)

Association of aPTT-Guided Anticoagulation Monitoring with Thromboembolic Events in Patients Receiving V-A ECMO Support: A Systematic Review and Meta-Analysis
by: Sasa Rajsic, et al.
Published: (2023-04-01)

Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer
by: Alice Labianca, et al.
Published: (2020-07-01)

Immunological effects of anti-coagulant unfractionated heparin in pregnant Chinese women with cryptic recurrent miscarriages
by: Yanli Hong, et al.
Published: (2020-06-01)

New Insights in Thrombin Inhibition Structure–Activity Relationships by Characterization of Octadecasaccharides from Low Molecular Weight Heparin
by: Pierre A. J. Mourier, et al.
Published: (2017-03-01)

The Coagulopathy Bleeding in Disseminated Intravascular Coagulation. Therapy by Heparin and Treatment Plasmapheresis
by: Kurgan M., et al.
Published: (2015-12-01)

An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation
by: Yuan Teng, et al.
Published: (2022-06-01)

Heparin: Past, Present, and Future
by: Eziafa I. Oduah, et al.
Published: (2016-07-01)

Establishing reference ranges and normal values for coagulation screening in healthy Indian male volunteers enrolled for a longitudinal study
by: Rehan Ahmed, et al.
Published: (2019-01-01)

Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO
by: Alexander S. Streng, et al.
Published: (2020-10-01)

Coronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome
by: A. D. Makatsariya, et al.
Published: (2020-07-01)

Therapeutic inefficacy of protocol driven intravenous unfractionated heparin infusion in the current era
by: Kayla Torppey, et al.
Published: (2023-10-01)

Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients
by: Armando Tripodi, et al.
Published: (2023-06-01)

Successful use of an antithrombin for heparin resistance with andexanet alfa
by: Jun Honda, et al.
Published: (2023-05-01)

Autoimmune Heparin-Induced Thrombocytopenia
by: Theodore E. Warkentin
Published: (2023-11-01)

In Vitro Modeling of the Influence of FVIII Activity and Heparin Induced Prolongation of APTT
by: Aida Mehmedagić, et al.
Published: (2008-08-01)

Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study
by: Mouhamed Djahoum Moussa, et al.
Published: (2021-05-01)

Heparin‐induced hyperkalemia, can LMWH cause hyperkalemia? A systematic review
by: Gedion Yilma Amdetsion, et al.
Published: (2023-11-01)

Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay
by: Paul Billoir, et al.
Published: (2022-09-01)

Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC): study protocol for a multicenter randomized controlled trial
by: Yini Sun, et al.
Published: (2024-01-01)

The comparing of acute effects of two training models aerobic and resistance on the clotting times in young women students
by: M. Rahmani Ghobadi, et al.
Published: (2018-12-01)

INTRAOPERATIVE ANTICOAGULATION MONITORIZATION IN VASCULAR SURGERY – DOES A BLIND DOSIS FITS ALL?
by: Nuno Henriques Coelho, et al.
Published: (2019-05-01)

Effectiveness of early heparin therapy on outcomes in critically ill patients with sepsis-induced coagulopathy
by: Jia-Jia Huang, et al.
Published: (2023-05-01)

Does ‘heparin-induced thrombocytopenia’ hit our minds?
by: Arun R. Thangavel, et al.
Published: (2016-08-01)

Coagulation Profile Study in Pregnancy Induced Hypertension
by: Dr.Hiral R. Kavar, et al.
Published: (2023-06-01)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
by: Osamu Kumano, et al.
Published: (2021-03-01)

Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients
by: Mahmut Yüksel, et al.
Published: (2009-12-01)

Comparison of Pregnancy Outcomes of Low Molecular Weight Heparin with Unfractionated Heparin in the Treatment of Recurrent Abortion Secondary to Antiphospholipid Syndrome
by: M Janghorbani, et al.
Published: (2013-09-01)

The Antineoplastic Effect of Heparin on Colorectal Cancer: A Review of the Literature
by: Emmanuel Giannas, et al.
Published: (2023-11-01)

Analysis of D-Dimer Level and Prothombin Time (PT) Activated Prothombin Thromboplastin (APTT) on Heparin Administration to COVID-19 Patients
by: Dela Yorike, et al.
Published: (2022-04-01)

Low-molecular-weight heparin in patients with renal insufficiency
by: AG Fischer
Published: (2009-08-01)